HEADER OXYGEN STORAGE/TRANSPORT 17-NOV-02 1O1J TITLE DEOXY HEMOGLOBIN (A-GLY-C:V1M,L29F,H58Q; B,D:V1M,L106W) COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEMOGLOBIN ALPHA CHAIN; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: DEOXYHEMOGLOBIN ALPHA CHAIN; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES; COMPND 7 MOL_ID: 2; COMPND 8 MOLECULE: HEMOGLOBIN BETA CHAIN; COMPND 9 CHAIN: B, D; COMPND 10 SYNONYM: DEOXYHEMOGLOBIN BETA CHAIN; COMPND 11 ENGINEERED: YES; COMPND 12 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 CELL: RED BLOOD CELL; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 MOL_ID: 2; SOURCE 9 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 10 ORGANISM_COMMON: HUMAN; SOURCE 11 ORGANISM_TAXID: 9606; SOURCE 12 CELL: RED BLOOD CELL; SOURCE 13 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 14 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS HEME, OXYGEN DELIVERY VEHICLE, BLOOD SUBSTITUTE, OXYGEN STORAGE- KEYWDS 2 TRANSPORT COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR E.A.BRUCKER REVDAT 7 16-AUG-23 1O1J 1 REMARK REVDAT 6 27-OCT-21 1O1J 1 REMARK SEQADV LINK REVDAT 5 24-JUL-19 1O1J 1 REMARK REVDAT 4 23-AUG-17 1O1J 1 SOURCE REMARK REVDAT 3 24-FEB-09 1O1J 1 VERSN REVDAT 2 28-FEB-06 1O1J 1 JRNL REMARK REVDAT 1 18-DEC-02 1O1J 0 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH E.A.BRUCKER REMARK 1 TITL GENETICALLY CROSSLINKED HEMOGLOBIN: A STRUCTURAL STUDY REMARK 1 REF ACTA CRYSTALLOGR.,SECT.D V. 56 812 2000 REMARK 1 REFN ISSN 0907-4449 REMARK 1 DOI 10.1107/S0907444900006557 REMARK 1 REFERENCE 2 REMARK 1 AUTH D.H.DOHERTY,M.P.DOYLE,S.R.CURRY,R.J.VALI,T.J.FATTOR, REMARK 1 AUTH 2 J.S.OLSON,D.D.LEMON REMARK 1 TITL RATE OF REACTION WITH NITRIC OXIDE DETERMINES THE REMARK 1 TITL 2 HYPERTENSIVE EFFECT OF CELL-FREE HEMOGLOBIN REMARK 1 REF NAT.BIOTECHNOL. V. 16 672 1998 REMARK 1 REFN ISSN 1087-0156 REMARK 1 REFERENCE 3 REMARK 1 AUTH D.LOOKER,D.ABBOT-BROWN,P.COZART,S.DURFEE,S.HOFFMAN, REMARK 1 AUTH 2 A.J.MATHEWS,J.MILLER-ROEHRICH,S.SHOEMAKER,S.TRIMBLE,G.FERMI, REMARK 1 AUTH 3 N.H.KOMIYAMA,K.NAGAI,G.L.STETLER REMARK 1 TITL A HUMAN RECOMBINANT HEMOGLOBIN DESIGNED FOR USE AS A BLOOD REMARK 1 TITL 2 SUBSTITUTE REMARK 1 REF NATURE V. 356 258 1992 REMARK 1 REFN ISSN 0028-0836 REMARK 1 DOI 10.1038/356258A0 REMARK 2 REMARK 2 RESOLUTION. 1.90 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.90 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 88.1 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.164 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.159 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.229 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 10.130 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 3945 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 38304 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.151 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.146 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.214 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 10.160 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 3557 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 35024 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4406 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 172 REMARK 3 SOLVENT ATOMS : 370 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 4941.0 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 0.00 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : 0 REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 19795 REMARK 3 NUMBER OF RESTRAINTS : 23143 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.005 REMARK 3 ANGLE DISTANCES (A) : 0.015 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : 0.004 REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : NULL REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.034 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.037 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.015 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : NULL REMARK 3 SIMILAR ADP COMPONENTS (A**2) : NULL REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER, J.MOL.BIOL. 91(1973) 201-228 REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH AND HUBER REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1O1J COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 27-NOV-02. REMARK 100 THE DEPOSITION ID IS D_1000001686. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-APR-98 REMARK 200 TEMPERATURE (KELVIN) : 295.0 REMARK 200 PH : 6.50 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : SIEMENS REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : COLLIMATOR REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IIC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XDS REMARK 200 DATA SCALING SOFTWARE : XSCALE, XDS REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 39493 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.900 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 90.7 REMARK 200 DATA REDUNDANCY : 3.540 REMARK 200 R MERGE (I) : 0.05500 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 27.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.00 REMARK 200 COMPLETENESS FOR SHELL (%) : 79.2 REMARK 200 DATA REDUNDANCY IN SHELL : 3.06 REMARK 200 R MERGE FOR SHELL (I) : 0.30400 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 7.150 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: PDB ENTRY 1ABY REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 33.20 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.84 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: PH 6.50 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 41.73500 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 10600 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 23740 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -108.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 75 46.97 -150.10 REMARK 500 LEU A 113 64.59 -119.01 REMARK 500 VAL A 143 165.29 63.63 REMARK 500 ASP A 217 40.56 -143.17 REMARK 500 HIS B 2 97.76 63.85 REMARK 500 ASN B 80 55.03 -153.96 REMARK 500 HIS D 2 111.80 33.07 REMARK 500 ASN D 80 66.88 -153.40 REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM A 284 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS A 87 NE2 REMARK 620 2 HEM A 284 NA 101.6 REMARK 620 3 HEM A 284 NB 101.6 87.3 REMARK 620 4 HEM A 284 NC 102.2 156.2 87.5 REMARK 620 5 HEM A 284 ND 102.0 87.7 156.4 87.9 REMARK 620 N 1 2 3 4 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM A 285 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS A 229 NE2 REMARK 620 2 HEM A 285 NA 100.4 REMARK 620 3 HEM A 285 NB 100.0 87.5 REMARK 620 4 HEM A 285 NC 100.7 158.9 88.2 REMARK 620 5 HEM A 285 ND 101.0 88.2 159.0 88.5 REMARK 620 N 1 2 3 4 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM B 147 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS B 92 NE2 REMARK 620 2 HEM B 147 NA 100.2 REMARK 620 3 HEM B 147 NB 100.6 87.8 REMARK 620 4 HEM B 147 NC 100.8 159.0 88.6 REMARK 620 5 HEM B 147 ND 100.4 87.7 159.0 88.3 REMARK 620 N 1 2 3 4 REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 HEM D 147 FE REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HIS D 92 NE2 REMARK 620 2 HEM D 147 NA 100.1 REMARK 620 3 HEM D 147 NB 100.6 87.6 REMARK 620 4 HEM D 147 NC 100.9 159.1 88.3 REMARK 620 5 HEM D 147 ND 100.5 88.1 158.9 88.3 REMARK 620 N 1 2 3 4 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM A 284 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM A 285 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM B 147 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HEM D 147 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1O1I RELATED DB: PDB REMARK 900 CYANOMET HEMOGLOBIN (A-GLY-C:V1M,L29F,H58Q; B,D:V1M,L106W) REMARK 900 RELATED ID: 1O1K RELATED DB: PDB REMARK 900 DEOXY HEMOGLOBIN (A,C:V1M; B,D:V1M,V67W) REMARK 900 RELATED ID: 1O1L RELATED DB: PDB REMARK 900 DEOXY HEMOGLOBIN (A-GLY-C:V1M,L29W,H58Q; B,D:V1M) REMARK 900 RELATED ID: 1O1M RELATED DB: PDB REMARK 900 DEOXY HEMOGLOBIN (A-GLYGLYGLY-C:V1M,L29F,H58Q B,D:V1M,V67W) REMARK 900 RELATED ID: 1O1N RELATED DB: PDB REMARK 900 DEOXY HEMOGLOBIN (A-GLYGLYGLY-C:V1M,L29W; B,D:V1M) REMARK 900 RELATED ID: 1O1O RELATED DB: PDB REMARK 900 DEOXY HEMOGLOBIN (A,C:V1M,V67L; B,D:V1M, V67L) REMARK 900 RELATED ID: 1O1P RELATED DB: PDB REMARK 900 DEOXY HEMOGLOBIN (A-GLY-C:V1M; B,D: V1M, C93A, N108K) REMARK 999 REMARK 999 SEQUENCE REMARK 999 HUMAN HEMOGLOBIN HAS TWO ALPHA CHAINS WHICH ARE CALLED REMARK 999 CHAINS A AND C IN OTHER PDB FILES. IN THIS ENTRY THE TWO REMARK 999 ALPHA CHAINS HAVE BEEN COVALENTLY JOINED TOGETHER BY ONE REMARK 999 GLYCINE RESIDUE TO FORM ONE COVALENTLY LINKED POLYPEPTIDE REMARK 999 CHAIN. DBREF 1O1J A 1 141 UNP P69905 HBA_HUMAN 1 141 DBREF 1O1J A 143 283 UNP P69905 HBA_HUMAN 1 141 DBREF 1O1J B 1 146 UNP P68871 HBB_HUMAN 1 146 DBREF 1O1J D 1 146 UNP P68871 HBB_HUMAN 1 146 SEQADV 1O1J MET A 1 UNP P69905 VAL 1 ENGINEERED MUTATION SEQADV 1O1J PHE A 29 UNP P69905 LEU 29 ENGINEERED MUTATION SEQADV 1O1J GLN A 58 UNP P69905 HIS 58 ENGINEERED MUTATION SEQADV 1O1J GLY A 142 UNP P69905 LINKER SEQADV 1O1J PHE A 171 UNP P69905 LEU 29 ENGINEERED MUTATION SEQADV 1O1J GLN A 200 UNP P69905 HIS 58 ENGINEERED MUTATION SEQADV 1O1J MET B 1 UNP P68871 VAL 1 ENGINEERED MUTATION SEQADV 1O1J TRP B 106 UNP P68871 LEU 106 ENGINEERED MUTATION SEQADV 1O1J MET D 1 UNP P68871 VAL 1 ENGINEERED MUTATION SEQADV 1O1J TRP D 106 UNP P68871 LEU 106 ENGINEERED MUTATION SEQRES 1 A 283 MET LEU SER PRO ALA ASP LYS THR ASN VAL LYS ALA ALA SEQRES 2 A 283 TRP GLY LYS VAL GLY ALA HIS ALA GLY GLU TYR GLY ALA SEQRES 3 A 283 GLU ALA PHE GLU ARG MET PHE LEU SER PHE PRO THR THR SEQRES 4 A 283 LYS THR TYR PHE PRO HIS PHE ASP LEU SER HIS GLY SER SEQRES 5 A 283 ALA GLN VAL LYS GLY GLN GLY LYS LYS VAL ALA ASP ALA SEQRES 6 A 283 LEU THR ASN ALA VAL ALA HIS VAL ASP ASP MET PRO ASN SEQRES 7 A 283 ALA LEU SER ALA LEU SER ASP LEU HIS ALA HIS LYS LEU SEQRES 8 A 283 ARG VAL ASP PRO VAL ASN PHE LYS LEU LEU SER HIS CYS SEQRES 9 A 283 LEU LEU VAL THR LEU ALA ALA HIS LEU PRO ALA GLU PHE SEQRES 10 A 283 THR PRO ALA VAL HIS ALA SER LEU ASP LYS PHE LEU ALA SEQRES 11 A 283 SER VAL SER THR VAL LEU THR SER LYS TYR ARG GLY VAL SEQRES 12 A 283 LEU SER PRO ALA ASP LYS THR ASN VAL LYS ALA ALA TRP SEQRES 13 A 283 GLY LYS VAL GLY ALA HIS ALA GLY GLU TYR GLY ALA GLU SEQRES 14 A 283 ALA PHE GLU ARG MET PHE LEU SER PHE PRO THR THR LYS SEQRES 15 A 283 THR TYR PHE PRO HIS PHE ASP LEU SER HIS GLY SER ALA SEQRES 16 A 283 GLN VAL LYS GLY GLN GLY LYS LYS VAL ALA ASP ALA LEU SEQRES 17 A 283 THR ASN ALA VAL ALA HIS VAL ASP ASP MET PRO ASN ALA SEQRES 18 A 283 LEU SER ALA LEU SER ASP LEU HIS ALA HIS LYS LEU ARG SEQRES 19 A 283 VAL ASP PRO VAL ASN PHE LYS LEU LEU SER HIS CYS LEU SEQRES 20 A 283 LEU VAL THR LEU ALA ALA HIS LEU PRO ALA GLU PHE THR SEQRES 21 A 283 PRO ALA VAL HIS ALA SER LEU ASP LYS PHE LEU ALA SER SEQRES 22 A 283 VAL SER THR VAL LEU THR SER LYS TYR ARG SEQRES 1 B 146 MET HIS LEU THR PRO GLU GLU LYS SER ALA VAL THR ALA SEQRES 2 B 146 LEU TRP GLY LYS VAL ASN VAL ASP GLU VAL GLY GLY GLU SEQRES 3 B 146 ALA LEU GLY ARG LEU LEU VAL VAL TYR PRO TRP THR GLN SEQRES 4 B 146 ARG PHE PHE GLU SER PHE GLY ASP LEU SER THR PRO ASP SEQRES 5 B 146 ALA VAL MET GLY ASN PRO LYS VAL LYS ALA HIS GLY LYS SEQRES 6 B 146 LYS VAL LEU GLY ALA PHE SER ASP GLY LEU ALA HIS LEU SEQRES 7 B 146 ASP ASN LEU LYS GLY THR PHE ALA THR LEU SER GLU LEU SEQRES 8 B 146 HIS CYS ASP LYS LEU HIS VAL ASP PRO GLU ASN PHE ARG SEQRES 9 B 146 LEU TRP GLY ASN VAL LEU VAL CYS VAL LEU ALA HIS HIS SEQRES 10 B 146 PHE GLY LYS GLU PHE THR PRO PRO VAL GLN ALA ALA TYR SEQRES 11 B 146 GLN LYS VAL VAL ALA GLY VAL ALA ASN ALA LEU ALA HIS SEQRES 12 B 146 LYS TYR HIS SEQRES 1 D 146 MET HIS LEU THR PRO GLU GLU LYS SER ALA VAL THR ALA SEQRES 2 D 146 LEU TRP GLY LYS VAL ASN VAL ASP GLU VAL GLY GLY GLU SEQRES 3 D 146 ALA LEU GLY ARG LEU LEU VAL VAL TYR PRO TRP THR GLN SEQRES 4 D 146 ARG PHE PHE GLU SER PHE GLY ASP LEU SER THR PRO ASP SEQRES 5 D 146 ALA VAL MET GLY ASN PRO LYS VAL LYS ALA HIS GLY LYS SEQRES 6 D 146 LYS VAL LEU GLY ALA PHE SER ASP GLY LEU ALA HIS LEU SEQRES 7 D 146 ASP ASN LEU LYS GLY THR PHE ALA THR LEU SER GLU LEU SEQRES 8 D 146 HIS CYS ASP LYS LEU HIS VAL ASP PRO GLU ASN PHE ARG SEQRES 9 D 146 LEU TRP GLY ASN VAL LEU VAL CYS VAL LEU ALA HIS HIS SEQRES 10 D 146 PHE GLY LYS GLU PHE THR PRO PRO VAL GLN ALA ALA TYR SEQRES 11 D 146 GLN LYS VAL VAL ALA GLY VAL ALA ASN ALA LEU ALA HIS SEQRES 12 D 146 LYS TYR HIS HET HEM A 284 43 HET HEM A 285 43 HET HEM B 147 43 HET HEM D 147 43 HETNAM HEM PROTOPORPHYRIN IX CONTAINING FE HETSYN HEM HEME FORMUL 4 HEM 4(C34 H32 FE N4 O4) FORMUL 8 HOH *370(H2 O) HELIX 1 1 SER A 3 GLY A 18 1 16 HELIX 2 2 HIS A 20 PHE A 36 1 17 HELIX 3 3 PRO A 37 PHE A 43 5 7 HELIX 4 4 SER A 52 HIS A 72 1 21 HELIX 5 5 ASP A 75 LEU A 80 1 6 HELIX 6 6 LEU A 80 LYS A 90 1 11 HELIX 7 7 PRO A 95 LEU A 113 1 19 HELIX 8 8 THR A 118 THR A 137 1 20 HELIX 9 9 SER A 145 GLY A 160 1 16 HELIX 10 10 HIS A 162 PHE A 178 1 17 HELIX 11 11 PRO A 179 PHE A 185 5 7 HELIX 12 12 SER A 194 HIS A 214 1 21 HELIX 13 13 ASP A 217 LEU A 222 1 6 HELIX 14 14 LEU A 222 LYS A 232 1 11 HELIX 15 15 PRO A 237 LEU A 255 1 19 HELIX 16 16 THR A 260 THR A 279 1 20 HELIX 17 17 THR B 4 GLY B 16 1 13 HELIX 18 18 ASN B 19 TYR B 35 1 17 HELIX 19 19 PRO B 36 GLY B 46 5 11 HELIX 20 20 THR B 50 ASN B 57 1 8 HELIX 21 21 ASN B 57 LEU B 75 1 19 HELIX 22 22 ALA B 76 ASP B 79 5 4 HELIX 23 23 ASN B 80 LYS B 95 1 16 HELIX 24 24 PRO B 100 GLY B 119 1 20 HELIX 25 25 LYS B 120 PHE B 122 5 3 HELIX 26 26 THR B 123 HIS B 143 1 21 HELIX 27 27 THR D 4 GLY D 16 1 13 HELIX 28 28 ASN D 19 TYR D 35 1 17 HELIX 29 29 PRO D 36 GLY D 46 5 11 HELIX 30 30 THR D 50 ASN D 57 1 8 HELIX 31 31 ASN D 57 ALA D 76 1 20 HELIX 32 32 ASN D 80 LYS D 95 1 16 HELIX 33 33 PRO D 100 GLY D 119 1 20 HELIX 34 34 LYS D 120 PHE D 122 5 3 HELIX 35 35 THR D 123 ALA D 142 1 20 LINK NE2 HIS A 87 FE HEM A 284 1555 1555 2.09 LINK NE2 HIS A 229 FE HEM A 285 1555 1555 2.12 LINK NE2 HIS B 92 FE HEM B 147 1555 1555 2.09 LINK NE2 HIS D 92 FE HEM D 147 1555 1555 2.08 SITE 1 AC1 15 TYR A 42 PHE A 43 HIS A 45 PHE A 46 SITE 2 AC1 15 GLN A 58 LYS A 61 LEU A 83 LEU A 86 SITE 3 AC1 15 HIS A 87 LEU A 91 VAL A 93 ASN A 97 SITE 4 AC1 15 PHE A 98 LEU A 101 LEU A 136 SITE 1 AC2 14 TYR A 184 PHE A 185 HIS A 187 GLN A 200 SITE 2 AC2 14 LYS A 203 LEU A 228 HIS A 229 LEU A 233 SITE 3 AC2 14 VAL A 235 ASN A 239 PHE A 240 LEU A 278 SITE 4 AC2 14 HOH A1027 HOH A1287 SITE 1 AC3 16 ALA A 53 HOH A1036 PHE B 41 PHE B 42 SITE 2 AC3 16 HIS B 63 VAL B 67 LEU B 91 HIS B 92 SITE 3 AC3 16 LEU B 96 PHE B 103 TRP B 106 VAL B 137 SITE 4 AC3 16 LEU B 141 HOH B1143 HOH B1229 HOH B1252 SITE 1 AC4 12 PHE D 41 PHE D 42 HIS D 63 LYS D 66 SITE 2 AC4 12 VAL D 67 LEU D 91 HIS D 92 LEU D 96 SITE 3 AC4 12 ASN D 102 TRP D 106 VAL D 137 LEU D 141 CRYST1 63.396 83.470 53.643 90.00 99.22 90.00 P 1 21 1 4 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015774 0.000000 0.002560 0.00000 SCALE2 0.000000 0.011980 0.000000 0.00000 SCALE3 0.000000 0.000000 0.018886 0.00000